Loading... Please wait.
Company profile
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Source:
Cofisem
-
Last Update:
10 Jan 2025
Key Executives
| Chief Executive Officer | Gavin Spencer | ||||
| Chief Financial Officer | Sandrine Gestin | ||||
| Chief Human Resources Officer | Sandrine Gestin | ||||
| Chief Scientific Officer | Doug Hubatsch | ||||
| Chief Business Development Officer | Emmet Purtill | ||||
| Source: Cofisem - Last Update: 10 Jan 2025 | |||||
Key figures
| Millenium | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Net sales | 6.903 | 3.271 | 7.233 | 12.907 | 6.855 |
| Consumed purchases | 18.406 | ||||
| Labour costs | 2.503 | ||||
| Operating profit | -17.056 | ||||
| Income tax | -478 | ||||
| Net income | -20.881 | -27.759 | -43.761 | -18.098 | -18.922 |
| Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | French_GAAP | IFRS | IFRS | IFRS | IFRS |
| Income from ordinary activities | 3.271 | 7.233 | 12.907 | 6.855 | |
| Operating income | -34.061 | -46.010 | -6.760 | -18.332 | |
| Cost of financial indebtedness net | 1.246 | 4.837 | 8.188 | 5.100 | |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income (Group share) | -27.759 | -43.761 | -18.098 | -18.922 | |
| Source: Cofisem - Last Update: 10 Jan 2025 | |||||
Shareholder information
Address
Nicox SA
Sundesk Sophia Antipolis, Bâtiment C Emerald Square Rue Evariste Galois
FR-06410
Biot
France
Phone number:
+33 (0)4 97 24 53 00
Source:
Cofisem
-
Last Update:
10 Jan 2025